[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642701":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":10,"responsibleParty":35,"collaborators":10,"id":37,"slug":10,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":10},{"fullName":5,"class":6},"CanSino Biologics Inc.","INDUSTRY",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Previously vaccinated with PCV13 (CanSino)",null,[12],"Other: Previously vaccinated with PCV13 (CanSino)",{"label":14,"type":10,"description":10,"interventionNames":15},"Previously vaccinated with PCV13 (Pfizer)",[16],"Other: Previously vaccinated with PCV13 (Pfizer)",[18,22],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":10},"OTHER","3.0 to 3.5 mL of venous blood will be collected for the immunodynamic study.",[9],{"type":19,"name":14,"description":20,"armGroupLabels":23,"otherNames":10},[14],[25],{"name":26,"affiliation":27,"role":28},"Zhiqiang Xie","Henan Provincial Center for Disease Control and Prevention","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Jiayi Huang","CONTACT","022-58213600-6051","jiayi.huang@cansinotech.com",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642701",false,"NCT07648641","A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197\u002FTetanus Toxoid)","Inclusion Criteria:\n\n* Participants in the 2-month-old (minimum 6 weeks) group from the previous Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV)\n* The legal guardian or authorized representative is willing to provide identification documents\n* The legal guardian or authorized representative has provided informed consent, voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol\n* The interval since the last dose of the primary vaccination series is ≥4 years\n\nExclusion Criteria:\n\n* Failure to complete blood draws at 1 and 2 years post-vaccination\n* Administration of any pneumonia vaccine after completion of the full vaccination series\n* Body temperature ≥37.3°C\n* Any other factors deemed by the investigator to render the participant unsuitable for participation in the clinical trial",true,"ALL","5 Years",{"count":47,"type":48},100,"ESTIMATED","OBSERVATIONAL","This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV), with 50 participants in each of the treatment and control groups, and who have completed blood sample collection for the 1-year and 2-year immunogenicity studies. All participants will have 3.0-3.5 mL of venous blood collected for the immunogenicity study.",[52,53,54],"Pneumococcal Infections","Streptococcal Infections","Bacterial Infections",[56,57,52,58],"PCV13","13 valent Pneumococcal conjugate vaccine","Immune persistence","NOT_YET_RECRUITING","2026-06-10",{"date":62,"type":63},"2026-06-15","ACTUAL",{"date":65,"type":48},"2026-07-01",{"date":67,"type":48},"2027-12-01",{"name":5,"class":6}]